In millions of USD; shares in millions, except per-share amounts
Q2 FY2026
As of Jun 30, 2026
Q1 FY2026
As of Mar 31, 2026
Q4 FY2025
As of Dec 31, 2025
Q3 FY2025
As of Sep 30, 2025
Q2 FY2025
As of Jun 30, 2025
Q1 FY2025
As of Mar 31, 2025
Q4 FY2024
As of Dec 31, 2024
Q3 FY2024
As of Sep 30, 2024
Q2 FY2024
As of Jun 30, 2024
Q1 FY2024
As of Mar 31, 2024
Q4 FY2023
As of Dec 31, 2023
Q3 FY2023
As of Sep 30, 2023
Q2 FY2023
As of Jun 30, 2023
Q1 FY2023
As of Mar 31, 2023
Q4 FY2022
As of Dec 31, 2022
Q3 FY2022
As of Sep 30, 2022
Q2 FY2022
As of Jun 30, 2022
Q1 FY2022
As of Mar 31, 2022
Q4 FY2021
As of Dec 31, 2021
Q3 FY2021
As of Sep 30, 2021
Assets
Current assets
Cash and cash equivalents
Accounts receivable, net
Accrued unbilled revenues
Inventories
Regulatory assets
Derivative instruments
Prepaid taxes
Prepayments and other
Total current assets
Property, plant and equipment, net
Other assets
Nuclear decommissioning fund and other investments
Regulatory assets
Derivative instruments
Operating lease right-of-use assets
Finance lease right-of-use assets
Other
Total other assets
Total assets
Liabilities and Equity
Current liabilities
Current portion of long-term debt
Short-term debt
Accounts payable
Regulatory liabilities
Taxes accrued
Accrued interest
Dividends payable
Derivative instruments
Operating lease liabilities
Other
Total current liabilities
Deferred credits and other liabilities
Deferred income taxes
Deferred investment tax credits
Regulatory liabilities
Asset retirement obligations
Derivative instruments
Customer advances
Pension and employee benefit obligations
Operating lease liabilities
Finance Lease, Liability, Noncurrent
Other
Deferred Credits and Other Liabilities, Noncurrent
Capitalization
Long-term debt
Common stock — 1,000,000,000 shares authorized of $2.50 par value; 624,405,747 and 623,600,715 shares outstanding at June 30, 2026 and December 31, 2025, respectively
